Get the Stockscreener App
3.04
3.03%
-0.095
After Hours:
2.97
-0.07
-2.30%
Grace Therapeutics Inc stock is traded at $3.04, with a volume of 20,980.
It is down -3.03% in the last 24 hours and up +0.00% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
See More
Previous Close:
$3.135
Open:
$3.1
24h Volume:
20,980
Relative Volume:
9.53
Market Cap:
$30.42M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.96
$3.1331
1-Week Range:
$2.96
$3.32
52-Week Range:
$2.96
$3.32
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-649-9272
Address
103 CARNEGIE CENTER, PRINCETON
Grace Therapeutics Inc Stock (GRCE) Latest News
GRCE: Initiating Coverage – From Confusion to Infusion - MSN
GRCE (Grace Therapeutics) Financial Strength : 9 (As of Jun. 2024) - GuruFocus.com
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Grace Therapeutics to host virtual KOL event on GTX-104 - Nasdaq
Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update - StockTitan
GRCE (Grace Therapeutics) Cash Flow from Financing : $7.36 Mil (TTM As of Jun. 2024) - GuruFocus.com
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial - Marketscreener.com
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 - The Manila Times
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR - MSN
Grace Expands Polypropylene Operating Capacity in India with Nayara Energy Limited - Yahoo Finance
Acasti Pharma Inc. Announces Resignation of Jean-Marie Canan from Board of Directors and Member of Audit Committee and Governance and Human Resources Committee - Marketscreener.com
Grace Therapeutics announces name change and new ticker - Investing.com India
KB Financial Group (NYSE:KB) Sets New 1-Year High – Should You Buy? - Defense World
Acasti Pharma transitions to Grace Therapeutics, trading as GRCE - Investing.com India
ACSTAcasti Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Hurco Poised to Pioneer the Future of Manufacturing - The Manila Times
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire
Student loan grace period expires: What borrowers need to know - Yahoo Finance
Acasti Pharma Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 - Marketscreener.com
Seeking Online Therapy as a Christian? Look No Further Than These 6 Companies - Verywell Mind
Gridspace Enhances Virtual Agent Grace with Groundbreaking Emotional Intelligence - Yahoo Finance
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update - StockTitan
Why the S&P 500 is poised to rocket 100% in 5 years - Yahoo Finance
H. Jack West, MD - Oncology News Central
‘Give Yourself Grace’ After a Cancer Diagnosis, Kristen Dahlgren Says - Curetoday.com
Relacorilant shows significant benefits in Cushing’s patients in trial - Cushing's Disease News
Andelyn Biosciences Partners With Grace Science To Advance GS-100 - Contract Pharma
This biotech incubator has built 100+ companies by asking, What if . . . ? - Fast Company
UPS Stock Should Continue to Grace Your Portfolio: Here's Why - Yahoo Finance
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance - Yahoo Finance
Acasti: Fiscal Q3 Earnings Snapshot - Marketscreener.com
AstraZeneca pays $1B to take the wheel of Gracell’s CAR-T ‘fast car’ - Fierce Biotech
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal - Reuters
AWS, Hoppr Launch Model to Accelerate Generative AI Tools in Medical Imaging - MedCity News
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule - Yahoo Finance
Halle Berry’s number one tip for going number two - Fast Company
SAEM GRACE: Phenobarbital for alcohol withdrawal management in the emergency department: A systematic review of direct evidencePunia2024Academic Emergency Medicine - Wiley Online Library
Chinese CAR T-maker Gracell raises $150M in private financing - BioWorld Online
Trial data for Cushing's treatments relacorilant, Korlym due next year - Cushing's Disease News
Biogen to Acquire Reata Pharmaceuticals - Vinson & Elkins LLP
Pear Therapeutics was sold for parts to four companies for about $6M last week. - Axios
NJ Bioscience Center-Incubator - NJEDA (.gov)
Corcept planning to seek relacorilant approval for Cushing’s in 2024 - Cushing's Disease News
Acasti Pharma Inc. to Proceed with Phase 3 Clinical Safety Study for GTX-104 - Marketscreener.com
GRACE Phase 3 trial of relacorilant nears complete enrollment - Cushing's Disease News
Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiency - Wiley Online Library
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 - Quantisnow
Nonprofit FAST Has Cure for Angelman Syndrome in Its Sights |... - Angelman Syndrome News
Tiny arms, big relief: Finally a COVID-19 vaccine for Mattie Grace - Walgreens Boots Alliance
Pfizer and Moderna rapidly falling out of favor as Americans' favorite brands: report - FiercePharma
Grace Therapeutics Inc Stock (GRCE) Financials Data
There is no financial data for Grace Therapeutics Inc (GRCE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):